Support from healthcare and pharmaceutical companies

Please refer to our policy to understand how we work with healthcare and pharmaceutical companies. Acceptance of donations does not mean that we endorse their products and under no circumstances can these companies influence our strategic direction, activities or the content of the information and support we provide to people affected by lymphoma.

Funding Received in 2021*

  • Janssen £8,000
  • Takeda £20,000
  • Gilead £30,696
  • AbbVie £12,000
  • Roche £21,000
  • Incyte Biosciences UK Ltd £20,000
  • Bristol Myers Squibb £20,000
  • Kyowa Kirin £16,800
  • Recordati Rare Diseases £4,800

Updated August 2021

Funding Received in 2020*

  • Gilead £41,339
  • AbbVie Ltd £23,885
  • AstraZeneca £37,000
  • Kyowa Kirin £14,000
  • Bristol Myers Squibb £35,000
  • Roche £20,000
  • Takeda £32,000
  • Janssen £45,000
  • Novartis £17,723
  • Recordati Rare Diseases UK £5,000

Updated January 2021

Funding received in 2019*

  • 4SC AG £750
  • AbbVie Ltd  £10,000
  • AstraZeneca £8,394
  • Bristol-Myers Squibb Pharmaceuticals Ltd £5,000
  • Celgene £20,000
  • Gilead Sciences Ltd £36,862
  • Janssen-Cilag Ltd £15,000
  • Kyowa Kirin Ltd £15,500
  • Mallinckrodt Pharmaceuticals £3,000
  • Novartis £10,410
  • Proton Partners International Ltd £750
  • Recordati Rare Diseases previously Orphan Europe £3,000
  • Roche Products Ltd £12,000
  • Takeda UK Ltd £27,750

*Updated Jan 2020

Funding received in 2018

  • AbbVie Ltd £13,000
  • Alliance Medical £1,200
  • Bayer AG £3,000
  • Bristol-Myers Squibb Pharmaceuticals Ltd £10,000
  • Celgene Ltd £15,000
  • Gilead Sciences Ltd £30,775
  • Janssen-Cilag Ltd  £10,950
  • Proton Therapy UK Ltd £500
  • Roche Products Ltd £13,500
  • Sandoz £5,000
  • Servier Laboratories Ltd  £1,500
  • Takeda UK Ltd £39,420